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paracrine DA system in cells of proximal tubules constitutesg-L-glutamyl-L-DOPA inhibits Na1-phosphate cotransport
a cellular basis for the potent and specific phosphaturic actionacross renal brush border membranes and increases renal ex-
of gludopa.cretion of phosphate.
Background. For treatment of phosphate (Pi) overload in
various pathophysiological states, an agent that selectively in-
creases renal Pi excretion would be of major value. Previously,
Regulation of renal excretion of inorganic phosphatewe have shown that dopamine (DA) inhibits Na1-Pi cotrans-
(Pi) is a key process in maintaining body Pi homeostasisport in renal epithelia. However, the administration of DA or
its immediate precursor L-DOPA increases DA in multiple [1]. Most of the Pi that is ultrafiltered in glomeruli is
tissues. Synthetic dipeptide g-L-glutamyl-L-DOPA (gludopa) reabsorbed in proximal tubules. Sodium-phosphate
can serve as an inactive precursor (pro-pro-drug) of DA. This
(Na1-Pi) cotransport across luminal brush border mem-study tested the hypothesis that, because of the unique colocali-
branes (BBM) is a rate-limiting [2] and regulated [3]zation of g-glutamyltransferase (g-GT), aromatic amino acid
decarboxylase, Na1-Pi cotransporter, and Na1-L-DOPA co- step in the translocation of Pi from lumen of proximal
transporter in brush border membrane (BBM) of proximal tubules to peritubular capillaries [1]. Diminished renal
tubular cells, gludopa may elicit phosphaturia by action of DA excretion of Pi in a variety of pathophysiological states,generated within the kidney.
such as hypoparathyroidism, pseudohypoparathyroid-Methods. Thyroparathyrectomized rats were given placebo,
ism, tumoral calcinosis, and, most frequently, renal insuf-or gludopa, or gludopa 1 g-GT inhibitor acivicin. Urinary
excretion of Pi, Ca21, Na1, K1, DA, cAMP, and cGMP was ficiency of various origins, results in chronic accumulation
determined, and Na1-Pi cotransport was measured in BBM and retention of Pi and in hyperphosphatemia [4–6]. A
prepared from kidneys of rats at the end of the experiment.
surfeit of Pi in renal insufficiency, in turn, leads to sec-Results. The administration of gludopa resulted in: (a) an
ondary hyperparathyroidism and results in renal osteo-inhibition of Na1-Pi cotransport, but not cotransport of Na1-
proline and Na1-alanine in BBM; (b) an increase (1300%) of dystrophy in its various manifestations [4, 5, 7].
fractional excretion (FE) of Pi and a drop (235%) of plasma In principle, Pi overload can be ameliorated by either
Pi, whereas the plasma levels and FEs of Ca21, Na1, and K1 dietary or pharmacotherapeutic maneuvers that reducewere unchanged; (c) an increase in urinary excretion of cAMP,
the quantum of Pi that is absorbed in the gastrointestinalbut not cGMP; (d) a 1000-fold increase of urinary excretion
of DA, without a change in excretion of norepinephrine; and tract [4, 5, 7], an increase of renal Pi excretion [8–11],
(e) an incubation of gludopa with BBM in vitro, which caused or a combination of both. The decrease of Pi quantum
a release of L-DOPA, and the in vivo administration of acivicin, absorbed from small intestine can be achieved by dietarywhich blocked actions of gludopa to inhibit Na1-Pi cotransport
restriction of the amount of ingested Pi, that is, feedingand to increase urinary excretions of Pi and DA.
with low-Pi diet and/or with the use of “Pi binders,”Conclusions. We conclude that colocalization of enzymes
of biotransformation, BBM transporters, and the autocrine/ cationic compounds that bind dietary Pi in intestinal
lumen and prevent its absorption across the wall of the
small intestine [4, 5, 7]. However, therapeutic measuresKey words: dopamine, gludopa, phosphaturia, acivicin, brush border
membrane, renal excretion. to correct Pi overload, based on these principles, are still
unsatisfactory. A low Pi diet is difficult to design and
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Fig. 1. Scheme of biotransformation and ac-
tion of gludopa in proximal tubular cell, re-
sulting in increased phosphate (Pi) excretion.
Gludopa (g-glutamyl-L-DOPA) from glomer-
ular ultrafiltrate—tubular fluid binds as a sub-
strate to g-glutamyltransferase (1. g-GT) on
the surface of brush border membrane (BBM).
g-GT catalyzes release of L-DOPA, and
L-DOPA is translocated into cell interior by
the [Na1o] . [Na1i] gradient energized co-
transporter (s) across BBM [27]. In cyto-
plasm, L-DOPA is converted by L-aromatic
amino acid decarboxylase (2. L-AADC) to
dopamine that exits to interstitial fluid and
also into tubular lumen. Dopamine may act
also on the adjacent cells. Dopamine binds to
a dopamine receptor (DA1 subtype) that is
coupled to adenylate cyclase (AC) and in-
creases synthesis of cAMP; increased cAMP
activates protein kinase A (PKA) and thereby
inhibits Na1-Pi cotransporter (d) in BBM.
This inhibition is the basis for decreased Pi
reabsorption in proximal tubules and results in
phosphaturia (discussed earlier in this article).
aluminum- and calcium-based Pi binders has serious side in clinical practice [12, 14]. Thus, a suitable pharmaco-
therapy that would selectively increase the renal excre-effects [4, 5, 7], and this treatment modality also has a
low degree of patient compliance. Thus, in patients with tion of Pi is not available.
Via stimulating dopamine (DA) receptors (DA1 sub-mild or moderate renal insufficiency with partially pre-
served renal function or in patients with normal renal type) and by activating the cAMP signaling pathway,
dopamine elicits an inhibition of Na1-Pi cotransport infunction who retain Pi, such as hypoparathyroidism or
pseudohypopathyroidism [4], the availability of a novel cultured renal epithelial opossum kidney (OK) cells [15,
16], an established in vitro model of Na1-Pi cotransportpharmacotherapy that selectively increases the renal ex-
cretion of Pi would be of major benefit. in renal proximal tubules [15, 16]. Intravenous infusion of
DA to thyroparathyrectomized rats selectively decreasedTo date, however, attempts to increase renal Pi excre-
tion by pharmacological inhibition of Pi reabsorption in the Na1-Pi cotransport across renal BBM of proximal
tubules [6] and resulted in an increased fractional excre-proximal tubules has met with little success [12]. The
administration of parathyroid hormone (PTH), an arche- tion (FE) of Pi [17, 18]. Based on these observations,
we hypothesized that DA generated intrarenally, via thetypal hormone that elicits phosphaturia [2, 3], also pri-
marily increases tubular reabsorption of Ca21, mobilizes inhibition of Na1-Pi cotransport across BBM, can de-
crease proximal tubular reabsorption of Pi and elicit phos-bone Ca21, and can lead to hypercalcemia. Moreover,
PTH should be given by the parenteral route. The admin- phaturia [6, 15, 17, 18]. DA should be administered by
intravenous (i.v.) infusion and thence has multiple effectsistration of phosphonoformic acid (PFA), a specific com-
petitive inhibitor of Na1-Pi cotransport in the luminal in nonrenal organs, other than the increase of Pi excre-
tion. To specifically modulate renal tubular function, DABBM of proximal tubules [8, 9], markedly increases uri-
nary excretion of Pi in rats fed either normal- or low-Pi should be generated in situ in renal parenchyma.
Not only DA itself, but also its immediate precursor,diet [8, 9], and also in rats with experimental renal insuf-
ficiency because of 5/6 nephrectomy [10, 11]. However, 3,4-dihydroxyphenylalanine (L-DOPA), when added to
OK cells in vitro inhibits Na1-Pi cotransport [15, 16], andthe relatively low affinity of PFA (Ki > 1 mm) for Na1-Pi
cotransporter [8, 13] and concerns that have been raised in vivo administration of L-DOPA elicits phosphaturia
[18]. Aromatic L-amino acid decarboxylase (AADC), aabout potential toxic effects of larger doses of PFA when
administered to severely compromised patients [12, 14] cytosolic enzyme [19] that catalyzes decarboxylation of
L-DOPA to DA, is present exclusively in proximal tubulescurrently precluded its further preclinical testing and use
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Fig. 2. Plasma levels (A) and urinary excre-
tions (B) of Pi, Ca21, and Na1 and K1 in control
rats (C) and in rats injected with gludopa (GD).
Plasma levels are in mm, and urinary excretion
of electrolytes is expressed as a fractional ex-
cretion (% on ordinate) relative to urinary ex-
cretion and plasma level of creatinine (Methods
section). Urinary excretion of Pi was signifi-
cantly (P , 0.02) increased (D , 1300%),
whereas plasma level of Pi was significantly
(P , 0.05) decreased (D , 235%). Plasma
levels as well as urinary excretions (FE) of
Ca21, Na1, and K1 were not different between
controls and GD-treated rats. Each bar de-
notes mean 6 sem (N 5 5 to 6).
[20], and it stands to reason that DA generated from colocalization of g-GT and AADC in proximal tubules,
but not in other nephron segments [20, 26], should allowL-DOPA locally in proximal tubules can act as an auto-
crine/paracrine agent primarily on proximal tubule cells. the conversion of L-DOPA to DA in proximal tubules
When administered parenterally or orally, L-DOPA is by a two-step enzymatic reaction. Then in situ generated
decarboxylated to DA not only in the kidney but also DA can modulate the functions of proximal tubular cells,
in numerous extrarenal tissues [21], and as a result, gen- including the rate of Na1-Pi cotransport (Fig. 1).
erated DA has many other effects, including hemody- It is well known that the administration of gludopa to
namic effects, in many nonrenal tissues. Synthetic dipeptide humans [23, 24] and to experimental animals [28, 29]
g-L-glutamyl-L-dihydroxyphenylalanine (g-L-glutamyl-L- causes an increase in renal excretion of Na1 that is some-
DOPA, or gludopa) can serve as a pro-drug [22] of times accompanied with increases of glomerular filtra-
L-DOPA, and consequently of DA [21–24], in a manner tion rate, urine flow, and renal blood flow, but are with-
that is sharply targeted to the kidney [21]. Gludopa is out prohibitive side effects [23, 24, 30]. To date, the
enzymatically converted to L-DOPA by g-glutamyltrans- effects of gludopa on the renal excretion of Pi and ho-
peptidase (g-GT), a very highly active enzyme present meostasis of Pi have not been considered or investigated.
in the BBM of proximal tubules [25, 26], and the We experimentally tested the hypothesis that gludopa is
L-DOPA is transported across BBM [27] and then decar- converted to DA in proximal tubule cells, which inhibits
boxylated in proximal tubules by cytosolic AADC to Na1-Pi cotransport across BBM and elicits phosphaturia
DA [19, 20]. (g-GT catalyzes the enzymatic release of by the mechanism outlined in Figure 1.
L-DOPA from gludopa either by transpeptidation, that
is, glutamic acid forms a g-peptidic bond with another
METHODSamino acid, if available, or hydrolyzes gludopa to
Surgically thyroparathyroidectomized male rats weigh-L-DOPA and free glutamic acid [24]. Because it is not
ing 250 to 280 g were used for the in vivo experiments.known whether one or both types of reaction occurs in
Rats were kept in metabolic cages at least three daysvivo, we refer to action of g-GT to gludopa as the “re-
lease” or “generation” of L-DOPA from gludopa.) Thus, prior to the experiment while receiving free access to
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i.p. acivicin (10 mg/kg body wt) one hour prior to the
injection of gludopa, and a second dose of acivicin (10
mg/kg body wt) was administered simultaneously with
gludopa (20 mg/kg body wt). In the second group, rats
received gludopa (20 mg/kg body wt) only, and in the
third group, rats received only an i.p. injection of the
vehicle (5% glucose). To allow the comparison between
groups, experiments were conducted using a paired de-
sign [6, 9, 10]. That is, control rats and rats treated with
test agents were taken into the experiment at the same
date, were followed simultaneously, and were sacrificed
at the same day. Also, preparation of BBM, transport
and enzyme measurements, and other analyses were con-
ducted in the same experimental session using identical
reagents and procedures [6, 8–10, 17].
Brush border membrane vesicles were prepared with
the Mg21-precipitation method, as described in our previ-
ous studies [8, 9, 13]. The fraction of basolateral mem-
branes (BLM) was prepared by differential centrifuga-
tion and by the Percoll gradient centrifugation procedure
[34]. Activities of leucine aminopeptidase (LAP) and
g-GT in BBM and BLM were determined using chromo-
genic substrates, as described in our previous studies [8,
Fig. 3. Urinary excretions of cAMP and cGMP, dopamine, and norepi-
13, 25], and also Na1,K1-ATPase activity was deter-nephrine in control rats (C) and in rats injected with gludopa (GD).
Excretions of cAMP and cGMP are expressed as a percentage of change mined as an oubain-sensitive ATPase, also described in
relative to the paired control, taken as 100%. Excretions of cAMP (P , our previous communications [8, 13]. Protein concentra-
0.05) and of dopamine (P , 0.001) were (*) significantly increased (by
tion in fractions was determined using Lowry’s methodst-test). Excretions of dopamine and norepinephrine are expressed in
nmol/mg creatinine (ordinates). Each bar denotes mean 6 sem (N 5 7). [35]. The fraction of BBM showed significantly higher
activities of g-GT and LAP, and significantly lower activ-
ity of Na1,K1-ATPase as compared with BLM (Fig. 7).
The BLM had a significantly higher activity of Na1,K1-
standard rat chow and drinking water with the addition ATPase and, conversely, rather lower activities of g-GT
of 0.35% Ca21 glutamate. As reported [31], gludopa in- and LAP than BBM (Fig. 7).
jected intraperitoneally (i.p.) was rapidly absorbed (t1/2ab 5 To determine the rate of generation of L-DOPA from
6 min), and maximum plasma concentrations were main- gludopa in vitro, fractions of BBM and BLM prepared
tained for approximately two hours postinjection, fol- from normal rats were incubated with a substrate of 0.1
lowed by a monophasic elimination decline [31]. There- mm gludopa in a medium containing 40 mm Tris-HCl, 5 mm
fore, the maximum effect of gludopa can be anticipated glycine-glycine, and 0.01% (wt/vol) sodium metabisulfite
within a three hour time span after i.p. injection. In our (pH 5 7.4). The incubation was terminated by the addi-
experiments, rats were injected i.p. with either gludopa tion of ice-cold perchloric acid at a final concentration of
(20 mg/kg body wt) or controls with glutamic acid (5.24 5%. The precipitate was removed by centrifugation at
mg/kg body wt), both dissolved in 5% glucose. The dose 3800 3 g, and the content of L-DOPA in the supernatant
of 20 mg/kg body wt gludopa was chosen based on known was determined by high-performance liquid chromatog-
pharmacokinetics of gludopa in rat [31] and was 2.5 times raphy (HPLC) with electrochemical detection, as previ-
lower than a dose of 50 mg/kg, which elicits modest ously described [16, 36]. The content of DA and norepi-
natriuresis [32]. Rats were then kept in metabolic cages, nephrine in the urine was also determined by HPLC [36].
and urine was collected for the three-hour postinjection
Transport studies in BBM vesiclesperiod. At the end of three hours, rats were anesthetized
by an i.m. injection of 0.1 mg/100 g body wt of a solution The Na1-gradient–dependent uptakes of 32Pi, [3H]-L-
of equal volumes of 20 mg/ml xylazine and 100 mg/ml alanine, and [3H]-L-proline by BBM vesicles were mea-
ketamine hydrochloride [33]. Blood was collected. Kid- sured by the rapid filtration technique, as described in
neys were removed, and the dissected renal cortical tis- our previous communications [8, 9, 13, 25]. The initial
sue was used for isolation of BBM [8, 13]. concentrative “uphill” uptake was measured at 5 and
In experiments examining the effects of g-GT inhibitor 10 seconds, and uptake at the equilibrium period of 90
minutes [8, 13]. The Na1-independent uptakes of 32Piacivicin in vivo, one group of rats was injected first with
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Fig. 4. Capacity for Na1-gradient–dependent Na1-Pi cotransport (A),
Na1-[3H]-proline cotransport (B), and Na1-[3H]-alanine cotransport
across BBM isolated from kidneys of control rats (C) or rats injected
with gludopa (GD). All three transport systems were determined in
aliquots of the same preparation of BBM vesicles and are expressed
as an uptake of solute pmol/mg protein (ordinates) at indicated time
periods. (A) Na1-dependent uptake of Pi was significantly (t-test) lower
in GD-treated rats than in controls in the uphill concentrative phase,
at 5 (–31%) and 10 seconds (–28%), but not at the 90-minute equilibrium
point. In contrast, the capacity for Na1-dependent cotransports of [3H]-
proline (B) or of [3H]-alanine (C) was not different between controls
and GD-treated rats. Each bar denotes mean 6 sem (N 5 4 to 7).
and of [3H]-L-proline and [3H]-L-alanine were negligible wise, with the use of Student’s t-test for group or pair
(less than 8% of the uptake in the presence of Na1 comparisons, as appropriate. Values of P less than 0.05
gradient), and therefore, the values without Na1 were were considered statistically significant.
not routinely measured and subtracted [9, 25]. Urine
and plasma concentrations of Ca21, Na1, and K1 were
determined by atomic absorption spectrophotometry. Pi RESULTS
in plasma and urine was measured by Chen’s colorimet- Intraperitoneal administration of gludopa resulted in
ric methods [37]. Creatinine was determined by the col- at least a fourfold increase in FE of Pi (FEPi), but theorimetric method, and the content of cAMP and cGMP FEs of Ca21, Na1, and K1 were not changed (Fig. 2).
was determined by radioimmunoassay [38].
After three hours of gludopa injection, the plasma con-Gludopa was synthesized in the Mayo Clinic Protein
centration of Pi significantly decreased (235%), but noCore Facility. L-DOPA, glutamic acid, DA, and acivicin
significant changes were found in the plasma levels ofwere all purchased from Sigma (St. Louis, MO, USA).
Ca21, Na1, and K1 (Fig. 2). In response to gludopa, the32Pi, [3H]-L-proline, [3H]-L-alanine, and radioimmunoas-
urinary excretion of cAMP showed a significant increasesay kits for cAMP and cGMP were purchased from NEN
(D > 180%), but the excretion of cGMP did not change(Boston, MA, USA). Other chemicals, all of the highest
significantly (Fig. 3). Finally, in response to gludopa, thepurity grades available, were purchased from Sigma. The
results were evaluated statistically, unless stated other- urinary excretion of DA increased more than 1000-fold,
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Fig. 5. Kinetics of Na1-Pi cotransport inhibition in response to gludopa
as evaluated by a double-reciprocal plot. The Vmax for Na1-Pi cotransport Fig. 6. Correlation between the extent of decrease of Na1-Pi cotrans-in BBM from (s) (221 6 49 nmol Pi/second/mg protein, N 5 3) was port capacity of BBM and decrease of plasma levels of Pi in the samesignificantly (P , 0.05, paired t-test) lower than Vmax in BBM from corre- animals. Both parameters are expressed as -D% relative to paired con-sponding controls (d; 288 6 38 pmol/second/mg protein; N 5 3). On the trols that received solvent only, with the solid line representing theother hand, KmPi (242 6 34 mm Pi; N 5 3) did not significantly differ regression line, and dashed lines the 95% confidence limits. Ordinate,from KmPi for controls (232 6 26 mm Pi; N 5 3). Data are mean 6 sem. -D% of plasma [Pi]; abscissa, -D% of Na1-Pi cotransport, determined
as 32Pi uptake by BBM at five-second intervals (Methods and Fig. 4).
The correlation was significant: r 5 0.88 6 0.11, P , 0.05, t-test.
whereas urinary excretion of norepinephrine did not
change at all (Fig. 3).
BBM and BLM was almost completely inhibited by acivi-The Na1-gradient–dependent uptake of 32Pi by BBM
cin [38], a specific irreversible inhibitor of g-GT (Fig. 7).vesicles prepared from renal cortex of gludopa-injected
Finally, we investigated whether the release ofrats was markedly decreased (D > 230%) in the concen-
L-DOPA from gludopa by the action of g-GT was indeedtrative phase (Fig. 4). As measured in the same BBM
an essential first step in the biotransformation pathwaymembranes, the Na1-gradient–dependent uptake of
that produces phosphaturia (Fig. 1). The in vivo adminis-[3H]-L-proline or [3H]-L-alanine was not altered in re-
tration of acivicin [39] prior to and simultaneously withsponse to the administration of gludopa (Fig. 4). Neither
gludopa (discussed in the Methods section) completelyuptake of [3H]-L-proline, [3H]-L-alanine, nor 32Pi at equi-
blocked the decrease in Na1-gradient–dependent uptakelibrium period (90 min) was decreased (Fig. 4). The de-
of 32Pi across BBM, as well as abolished the increase in
crease in Na1-gradient–dependent uptake of 32Pi was due
urinary excretion of Pi and increase of urinary excretion
to a lower Vmax without a change in KmPi (Fig. 5). Because of DA (Fig. 8). The addition of acivicin in vitro to BBM
plasma for Pi determination was collected and kidneys
vesicles had no effect on Na1-dependent 32Pi uptake by
for the preparation of BBM were harvested at the same BBM (data not shown).
time, the relationship of these two parameters was exam-
ined. In response to gludopa administration, the D%
DISCUSSIONdecrease in rate of Na1-Pi cotransport across BBM
showed positive correlation with D% decrease of plasma The experimental results presented herein report that
Pi in the same rats (Fig. 6). When gludopa was added gludopa administered in vivo acts as a selective phospha-
directly in vitro to isolated BBM vesicles, the Na1-depen- turic agent and elucidate the mechanism of its action.
dent uptake of 32Pi was not changed (data not shown). Administration of gludopa decreased the capacity of
Incubation of gludopa with BBM in vitro resulted in Na1-gradient–dependent transport of 32Pi across renal
a time-dependent release of L-DOPA that was linear with BBM, but Na1-dependent cotransport of [3H]-L-proline
time at least up to 10 minutes (Fig. 7). In contrast, the or [3H]-L-alanine was not altered (Fig. 4). This finding
rate of L-DOPA release after incubation of gludopa with is similar to the effect of infused DA on BBM [6], and
BLM was five times lower than with BBM (Fig. 7). The suggests that administered gludopa did not cause a gen-
eralized inhibition of multiple Na1-gradient–dependentgeneration of L-DOPA from gludopa catalyzed both by
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Fig. 7. Activities of membrane-bound enzymes
in fraction of brush border membranes (BBM)
and fraction of basolateral membranes (BLM)
prepared from rat kidney cortex, and generation
of L-DOPA from gludopa by incubation with
BBM and BLM. BBMs are enriched in g-gluta-
myltransferase (g-GT; A) and leucine amino-
peptidase (LAP; B); BLMs are enriched in Na1,
K1-ATPase (C). (D) Generation of L-DOPA
from gludopa after incubation with either BLM
or BBM fractions from rat kidney cortex. Glu-
dopa (0.1 mm) was incubated with membrane
fractions for 10 minutes, and L-DOPA and
gludopa were determined by high-performance
liquid chromatography (Methods section). The
addition of acivicin, a g-glutamyltransferase in-
hibitor [38], suppressed generation of L-DOPA
from gludopa both in BBM and BLM; see black
portions at the bottom of the bars. The rate of
enzymatic release of L-DOPA from gludopa
was significantly (P , 0.01, t-test) higher in BBM
(D 1394%) than in BLM. Each bar denotes
mean 6 sem (N 5 3). (E) Under these experi-
mental conditions, L-DOPA generation from
gludopa was linearly proportional to a time of
at least up to 10 minutes (D), both by BBM
(d) and BLM (s). Data are the means 6 sem
from three experiments. Ordinates and the spe-
cific activities of enzymes: g-GT (mmol/min/mg
protein); LAP (nmol/min/mg protein); Na1,K1-
ATPase (mmol Pi/min/mg protein 3100). Each
bar denotes mean6sem (N53). *Denotes BBM
values significantly different between BLM.
transporters within BBM of proximal tubules. This ob- BBM sufficiently to noticeably influence the rate of Na1-Pi
servation also indicates that the decrease of Na1-Pi up- cotransport across BBM in situ [2, 8, 13]; moreover, the
take by BBM vesicles prepared from gludopa-treated decrease in [Na1o] . [Na1i] gradient would also affect
rats was not due to increased conductance of BBM for other Na1-solute cotransports in BBM. Furthermore,
Na1, a change that would cause a faster dissipation of DA decreases Na1-H1 antiport across BBM [42, 43] and
the [Na1o] . [Na1i] gradient, as it was observed in BBM thus the Na1 entry from tubular lumen. This factor would
prepared from uremic kidneys [40], because it should counteract the effect of decreased Na1,K1-ATPase on
similarly affect all Na1-solute cotransports. The lack of intracellular Na1 and on the [Na1o] . [Na1i] gradient.
change in uptake of [3H]-L-proline and [3H]-alanine by The kinetics of Na1-Pi cotransport across BBM in
BBM at the equilibrium period (90 min) also indicates response to gludopa, that is, the decreased Vmax without
that the volume of BBM vesicles was not altered in a change in KmPi (Fig. 5), resemble the changes of Na1-Pi
response to gludopa [8, 13, 25]. cotransport across BBM in response to phosphaturic hor-
As reported by other investigators, infusion of gludopa mones that act via cAMP [2, 3], and differ from the com-
decreases the activity of Na1,K1-ATPase in proximal
petitive inhibition of Na1-Pi cotransporter by phospha-
convoluted tubules [41]. Decreased Na1,K1-ATPase ac-
turic agents such as PFA that interact with BBM [8, 9].tivity may lead to a decrease of Na1 extrusion from the
This finding is consistent with the notion that Na1-Piinterior of proximal tubular cells across the BLM and
cotransport is not decreased because of the direct actionmay increase intracellular Na1 concentration, and hence,
of gludopa Na1-Pi cotransport. The addition of gludopait could decrease of [Na1o] . [Na1i] gradient across the
directly to BBM gludopa did not inhibit Na1-Pi cotrans-BBM. In principle, lower [Na1o] . [Na1i] gradient across
port in vitro, a finding also consistent with the notionBBM in situ may contribute to decrease of Na1-Pi reab-
that gludopa must be first converted to L-DOPA andsorption in intact cells. However, the nature of depen-
DA [44]. Our finding that L-DOPA is generated fromdence of Na1-Pi cotransport across BBM [2, 8, 13] on
gludopa at a much higher rate by BBM than by BLMthe external concentration of Na1 (KmNa1 > 70 mm)
(Fig. 7) is consistent with the predominant [25], but notindicates that a relatively modest decline in Na1,K1-
exclusive [45], localization of g-GT activity in BBM [8,ATPase activity in response to gludopa [40] is unlikely
to decrease the Na1 gradient [Na1o] . [Na1i] across 13, 25]. Suppression of L-DOPA formation from gludopa
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Fig. 8. Effect of g-GT inhibitor acivicin
(AVCN) on renal response to gludopa in vivo.
Fractional excretion of phosphate (FEPi; A),
urinary excretion of dopamine (B) and Na1-
Pi cotransport (C; measured as Na1-dependent
32Pi-uptake by BBM at five-seconds; values of
the control group is taken as 100% for paired
comparison) were compared using controls
(C), gludopa-treated (GD), and rats treated
with gludopa plus acivicin (GD 1 AFCN). See
Methods section for details. In A and B, each
bar denotes mean 6 sem (N 5 4). In C each
bar denotes mean 6 sem (N 5 3).
in vitro by the specific inhibitor acivicin (Fig. 7) affirms peritubular fluid [46]. Thus, DA has ready access to DA
receptors in membranes of proximal tubular cells, whichthat the reaction is catalyzed by g-GT.
Although the injection of L-DOPA resulted in an in- are likely to be the first structures that come into contact
with DA generated de novo from gludopa. The strikingcrease of DA both in kidney and in various other organs
[21], injection of gludopa increases DA content preferen- increase in urinary DA without significant change in
excretion of norepinephrine (Figs. 3 and 8) shows thattially in the kidney, in which the DA content increased
approximately 10 times or more than in other studied gludopa is converted to DA in non-neural tissues that
lack DA-b-hydroxylase.tissues [21]. This huge 1000-fold increase of urinary DA
in response to gludopa observed in our study (Fig. 3) To date, virtually all of the studies on gludopa have
been focused on investigating its antihypertensive andsuggests that, within the kidney parenchyma, enzymatic
conversion of gludopa to DA occurs specifically in proxi- natriuretic effects [21–24, 28–30]. It is amply documented
that gludopa administration causes natriuresis by inhib-mal tubules from where it egresses both to tubular and
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iting Na1 reabsorption in tubules [24, 27, 28, 40]. DA ently, gludopa has little or no side effects [22–24, 27, 30],
inhibits Na1 reabsorption in proximal tubules [40, 47] and the dipeptide is metabolized to natural molecules,
as well as in distal nephron segments, especially in col- that is, L-DOPA, DA, and glutamate. It should be
lecting ducts [48]. Natriuresis elicited by gludopa is likely stressed, however, that in this study we report on the
due to an inhibition of Na1 reabsorption both in proximal selective phosphaturic effect and basic mechanisms of
and distal tubular segments. Inhibition of Na1 reabsorp- gludopa action. Whether or not the phosphaturic effect
tion in collecting ducts probably determines the overall of gludopa is dose dependent, whether it persists after
rate of Na1 excretion; DA inhibits Na1,K1-ATPase in prolonged periods of administration, and how extensive
collecting ducts to an even greater degree than in proxi- it is in rats with intact parathyroid glands remains to be
mal tubules [48]. investigated in future studies. In this initial study, the
Dopamine is generated from gludopa only in proximal effect of gludopa was studied in thyroparathyrectomized
tubules, and it ought to be delivered to cells of distal rats to eliminate the effects of PTH and calcitonin on
segments, namely collecting ducts, either via tubular fluid Na1-Pi cotransport. This pathophysiological state resem-
or perhaps also via peritubular interstitial fluid. There- bles hypoparathyroid patients devoid of PTH, who retain
fore, we suggest that gludopa given in lower doses can Pi and in whom gludopa might be of therapeutic value.
generate a quantum of DA in situ that is adequate to According to preliminary results, gludopa increases FEPi
inhibit Na1-Pi cotransport and to decrease Pi reabsorp- in intact rats and in partially nephrectomized rats with
tion locally in proximal tubules, but such an amount of reduced renal function (abstract; Berndt et al, J Am Soc
DA is not sufficient to reach, and act on, distal tubular Nephrol 8:558A, 1997). The effect of gludopa in the
segments. As a consequence, at lower doses, gludopa syndrome of hyperparathyroidism remains to be exam-
can inhibit Na1-Pi cotransport (Fig. 4) and Pi reabsorp- ined. However, in this context, it is of interest that DA
tion (Fig. 2) in proximal tubules without causing natriure- was shown to sensitize the kidney to the phosphaturic
sis. A recent study showed that in lower doses, injected action of PTH [17].
gludopa increases urinary excretion of DA without rais- The bioavailability of gludopa administered orally was
ing Na1 excretion [28]. This feature should be an impor- reported to be low [30]. However, for reasons discussed
tant factor in designing the use of gludopa as a selective earlier in this study, the quantum of gludopa that is ad-
phosphaturic agent. sorbed from the intestine may not be sufficient to produce
The increase in urinary excretion of cAMP but not of natriuresis [28], but may be adequate for eliciting the
cGMP (Fig. 3) is consonant with the notion that DA, phosphaturic effect. Moreover, various maneuvers po-
generated in proximal tubules from gludopa, inhibits tentially may allow gludopa to be effective even when
Na1-Pi cotransport via activation of cAMP signaling
administered orally. For example, oral coadministrationpathway (Fig. 1), as it was documented in our previous
of gludopa with monoaminooxidase type B (MAO-B)studies of OK cells [15, 16]. DA receptors were found
inhibitor, which slows down DA catabolism, increased theboth in luminal BBM and antiluminal BLM of proximal
urinary excretion of Pi (T.P. Dousa, preliminary results).tubular cells [49]. However, adenylate cyclase activity in
In conclusion, this study reports a selective phosphatu-BLM is many-fold higher than in BBM [50], and there-
ric effect of gludopa and elucidates basic features offore, DA generated from gludopa acts on DA receptors
the mechanism by which gludopa, given in vivo, inhibits(probably DA1 subtypes) that are coupled positively to
Na1-Pi cotransport in the BBM of proximal tubules.adenylate cyclase in BLM [51].
Our results support the hypothesis that this phosphaturicDipeptide gludopa is a paradigm of an organ-targeted
effect of gludopa is due to the paracrine/autocrine actionpro-drug, where the specific site of action is determined
of DA generated in situ from the dipeptide in cells ofby cell phenotype, that is, expression of enzymes and
proximal tubules (Fig. 1). We surmise that the key as-transporters in the target cells. The initial and determin-
pects of gludopa’s phosphaturic effect make this com-ing step in the sequence leading to the conversion of
pound, in principle, potentially suited for novel, kidney-gludopa to L-DOPA is the action of g-GT, documented
targeted pharmacotherapy of Pi overload.by the finding that acivicin blocks the release of L-DOPA
in vitro (Fig. 7) and all effects of gludopa in vivo (Fig. 8).
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